178 related articles for article (PubMed ID: 26493254)
1. Missing the Forest for the Trees?: Drug-Eluting Balloon Treatment for Infrapopliteal Disease.
Tsai TT
JACC Cardiovasc Interv; 2015 Oct; 8(12):1623-5. PubMed ID: 26493254
[No Abstract] [Full Text] [Related]
2. Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries).
Zeller T; Beschorner U; Pilger E; Bosiers M; Deloose K; Peeters P; Scheinert D; Schulte KL; Rastan A; Brodmann M
JACC Cardiovasc Interv; 2015 Oct; 8(12):1614-22. PubMed ID: 26493253
[TBL] [Abstract][Full Text] [Related]
3. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain.
Zeller T; Brodmann M; Micari A; Keirse K; Peeters P; Tepe G; Scheinert D; Jaff MR; Rocha-Singh KJ; Li P; Schmahl R; Ansel GM;
Circ Cardiovasc Interv; 2019 Jan; 12(1):e007730. PubMed ID: 30630355
[No Abstract] [Full Text] [Related]
4. David versus Goliath: the first round.
Micari A; Vadalà G
JACC Cardiovasc Interv; 2014 Sep; 7(9):1057-9. PubMed ID: 25234680
[No Abstract] [Full Text] [Related]
5. Percutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Mahmud E
JACC Cardiovasc Interv; 2013 Mar; 6(3):290-2. PubMed ID: 23517841
[No Abstract] [Full Text] [Related]
6. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
Herten M; Torsello GB; Schönefeld E; Imm B; Osada N; Stahlhoff S
J Vasc Surg; 2015 Feb; 61(2):394-9. PubMed ID: 25307133
[TBL] [Abstract][Full Text] [Related]
7. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
8. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
Bertges DJ; Sedrakyan A; Sun T; Eslami MH; Schermerhorn M; Goodney PP; Beck AW; Cronenwett JL; Eldrup-Jorgensen J
Circ Cardiovasc Interv; 2020 Feb; 13(2):e008528. PubMed ID: 32069110
[TBL] [Abstract][Full Text] [Related]
9. The THUNDER trial results: clearing the way or ushering the storm?
Jaff MR
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):109-10. PubMed ID: 25616823
[No Abstract] [Full Text] [Related]
10. Commentary: comparative effectiveness of paclitaxel-based femoropopliteal interventions.
Armstrong EJ
J Endovasc Ther; 2014 Jun; 21(3):369-72. PubMed ID: 24915583
[No Abstract] [Full Text] [Related]
11. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
12. Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
Armstrong EJ; Laird JR
J Endovasc Ther; 2014 Feb; 21(1):9-11. PubMed ID: 24502478
[No Abstract] [Full Text] [Related]
13. Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Dinh K; Gomes ML; Thomas SD; Paravastu SCV; Holden A; Schneider PA; Varcoe RL
J Endovasc Ther; 2020 Apr; 27(2):175-185. PubMed ID: 32066315
[TBL] [Abstract][Full Text] [Related]
14. Thirty-six-month outcomes of drug-eluting balloon angioplasty in the infrapopliteal arteries.
Ozpak B; Bozok S; Cayir MC
Vascular; 2018 Oct; 26(5):457-463. PubMed ID: 29466934
[TBL] [Abstract][Full Text] [Related]
15. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
Stavroulakis K; Schwindt A; Torsello G; Stachmann A; Hericks C; Bosiers MJ; Beropoulis E; Stahlhoff S; Bisdas T
J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
[TBL] [Abstract][Full Text] [Related]
16. Commentary: how do we deal with dissection after angioplasty?
Fanelli F; Cannavale A; Gazzetti M; D'Adamo A
J Endovasc Ther; 2013 Dec; 20(6):801-4. PubMed ID: 24325696
[No Abstract] [Full Text] [Related]
17. Drug-coated balloons--the importance of packing and dosing antiproliferative drugs.
Hehrlein C
Catheter Cardiovasc Interv; 2015 Aug; 86(2):287-8. PubMed ID: 26198065
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Drug-Eluting Balloon and Standard Balloon Angioplasty for Infrapopliteal Arterial Diseases in Diabetic Patients.
Oz II; Serifoglu I; Bilici M; Altinbas NK; Oz EB; Akduman EI
Vasc Endovascular Surg; 2016 Nov; 50(8):534-540. PubMed ID: 28081691
[TBL] [Abstract][Full Text] [Related]
19. Commentary: aligning incentives of payer, facility, and provider: the lynchpin of providing more cost-effective care.
Sternbergh WC
J Endovasc Ther; 2013 Dec; 20(6):826-7. PubMed ID: 24325700
[No Abstract] [Full Text] [Related]
20. Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes.
Varcoe RL; Schouten O; Thomas SD; Lennox AF
JACC Cardiovasc Interv; 2016 Aug; 9(16):1721-8. PubMed ID: 27539693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]